Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension

NCT07707193 · tracked via the Priya Life Science Egypt tracker

Sponsor

Sohag University

Phase

Not applicable

Started

2026-07

Last updated

2026-07-16

Condition(s) studied

Schistosomiasis

Investigational drug(s) / intervention(s)

right heart catheterization for measure pulmonary artery pressure

right heart catheterization for measure pulmonary artery pressure: right heart catheterization for measure pulmonary artery pressure Through swan ganz catheter

Study summary

Pulmonary Arterial Hypertension is a progressive and potentially fatal cardiopulmonary disorder characterized by remodeling of the pulmonary vasculature, progressive elevation of pulmonary vascular resistance (PVR), and eventual right ventricular (RV) failure.

According to the 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines, pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure (mPAP) \>20 mmHg measured by right heart catheterization, while pulmonary arterial hypertension is additionally characterized by pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and PVR \>2 Wood units.

Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is classified within Group 1 PAH and represents one of the most important causes of PAH in endemic regions, particularly in developing countries such as Egypt and Brazil.

Schistosomiasis is considered the second most prevalent parasitic disease worldwide after malaria, affecting more than 200 million individuals globally. Chronic hepatosplenic schistosomiasis may lead to porto-systemic shunting, allowing parasite eggs to embolize into the pulmonary circulation, triggering chronic inflammation, endothelial dysfunction, and pulmonary vascular remodeling.

The pathological changes observed in Sch-PAH resemble those seen in idiopathic PAH, including medial hypertrophy, intimal fibrosis, and plexiform lesions. However, several studies suggest that patients with Sch-PAH may exhibit better long-term survival compared with idiopathic PAH despite comparable pulmonary hemodynamic impairment.

The mechanisms underlying this relatively favorable prognosis remain incompletely understood.

Right ventricular adaptation to increased afterload is currently recognized as one of the principal determinants of prognosis in PAH.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * All patients above 18 year diagnosed with schistozomiasis through history of exposure , serology , positive stool antigens ,Symmers' periportal fibrosis (the "clay pipe-stem" appearance) or Splenomegaly and suspected pulmonary hypertension through Probability Score" approach based on the 2022 ESC/ERS Exclusion Criteria: * All patients below 18 years old. * Left ventricular systolic or diastolic dysfunction. * Significant left-sided valvular heart disease. * severe chronic lung disease such as, Chronic obstructive pulmonary disease (COPD) ---- GOLD 4 and severe Interstitial lung disease (ILD). * Chronic Thromboembolic Pulmonary Hypertension. * Congenital heart diseases. * Severe hepatic or renal impairment unrelated to schistosomiasis. * Hemodynamically unstable patients. * Poor echocardiographic window preventing adequate RV assessment. * Active infection or acute systemic illness. * Refusal to participate in the study. * Significant arrhythmias affecting hemodynamic assessment (e.g., uncontrolled atrial fibrillation). * Previous heart or lung transplantation. * Pregnancy.

Primary outcome measure(s)

Right ventricular-pulmonary arterial coupling quantified by the TAPSE/PASP ratio measured by transthoracic echocardiography at baseline — 1 year
The tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) ratio will be measured by standard transthoracic echocardiography in all participants at the study assessment. TAPSE will be measured in millimeters (mm) using M-mode echocardiography, and PASP will be estimated in mmHg from the peak tricuspid regurgitation velocity. The TAPSE/PASP ratio (mm/mmHg) will be calculated for each participant and reported as a continuous variable (mean ± standard deviation or median \[interquartile range\], depending on data distribution).

Trial sites (1)

Facility	City	Region	Status
Mansoura university hospitals	Al Mansurah	Egypt

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon

Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting

Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting

Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon

Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07707193 on ClinicalTrials.gov ↗ ← All trials in Egypt